Article at Genomeweb: ”Stratipath Seeks to Ramp up Adoption of AI-Based Breast Cancer Test”
17 October 2024
Johan Hartman is a guest at the Johnson & Johnson
Being a leader in the field of AI-based precision diagnostics, Stratipath is constantly moving forward and evolving to provide new tools and strategies for improving patient outcomes. Keep track of developments in our news feeds, or follow us on LinkedIn or Twitter.
Being a leader in the field of AI-based precision diagnostics, Stratipath is constantly moving forward and evolving to provide new tools and strategies for improving patient outcomes. Keep track of developments in our news feeds, or follow us on LinkedIn or Twitter.
Johan Hartman is a guest at the Johnson & Johnson
Advances in breast cancer research are providing entirely new opportunities
Johan Hartman is a guest at the Johnson & Johnson
Stratipath is thrilled to announce a collaboration with Roche, the
In collaboration with iBreastBook, Johan Hartman, co-founder of Stratipath, participated
Stratipath, today announced that Stratipath Breast has received CE marking
new validation data for prognostic performance of Stratipath Breast in
Helsinki University Hospital (HUS), Finland’s largest healthcare provider and one
First world health tech: Press Release Stratipath releases biopsy capability
The ESMO Daily Reporter recently published a summary of the
A method for spatial interpretation of weakly supervised deep learning